D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma (CANF) to Hold from Buy with no price target after the company’s board approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio. The firm is lowering its rating ahead of the actual split, consistent with its policy, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Sets 1-for-3,000 Reverse Share Split and ADS Ratio Change Effective Early January 2026
- Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
- Can-Fite BioPharma Updates on Clinical Trials and Financials
- Can-Fite BioPharma provides clinical, financial update
- Can-Fite BioPharma to participate in BioFIT 2025